Optic Neuritis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OPT009 MIFTS: 53	Optic Neuritis Categories: Rare diseases, Eye diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis ¹² ⁷⁶ ⁵³ ³⁷ ⁵⁵ ⁶ ⁴⁴ ¹⁵ ⁷³

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the eye and adnexa

Disorders of optic nerve and visual pathways

Optic neuritis

External Ids:

Disease Ontology ¹² DOID:1210

ICD10 ³³ H46 H46.9

ICD9CM ³⁵ 377.3 377.30

MeSH ⁴⁴ D009902

NCIt ⁵⁰ C84950

SNOMED-CT ⁶⁸ 155189007 194051001 194052008 more

KEGG ³⁷ H01717

UMLS ⁷³ C0029134

Sources

Summaries for Optic Neuritis

NIH Rare Diseases : ⁵³ Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

MalaCards based summary : Optic Neuritis is related to neuromyelitis optica and optic nerve disease, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Th1 Differentiation Pathway and Toxoplasmosis. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete or partial loss of vision, eye and brain, and related phenotypes are behavior/neurological and hematopoietic system

Disease Ontology : ¹² An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia : ⁷⁶ Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Sources

Related Diseases for Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)

#	Related Disease	Score	Top Affiliating Genes
1	neuromyelitis optica	32.8	AQP4 HLA-DRB1 MBP MOG
2	optic nerve disease	32.2	AQP4 MBP MOG MT-ND4
3	transverse myelitis	30.9	AQP4 MBP TNF
4	panencephalitis, subacute sclerosing	30.9	MBP MOG
5	myelitis	30.7	AQP4 MBP MOG TNF
6	encephalitis	30.7	AQP4 CCR5 MOG
7	acute disseminated encephalomyelitis	30.6	AQP4 HLA-DRB1 MBP MOG
8	allergic encephalomyelitis	30.5	MBP MOG PLP1
9	pediatric multiple sclerosis	30.5	HLA-DRB1 MOG
10	rubella	30.4	HLA-DRB1 MOG TNF
11	panuveitis	30.3	HLA-DRB1 TNF
12	cytomegalovirus retinitis	30.3	CCR5 TNF
13	miller fisher syndrome	30.3	MAG TNF
14	neuroretinitis	30.2	AQP4 MOG
15	relapsing-remitting multiple sclerosis	30.2	AQP4 MBP MOG TNF
16	psoriatic arthritis	29.4	HLA-DRB1 LTA TNF
17	polyneuropathy	29.0	MAG MBP MPZ
18	polyradiculoneuropathy	28.9	MAG MBP MPZ
19	neuritis	28.8	AQP4 MAG MBP MOG MPZ MT-ND4
20	demyelinating disease	28.7	AQP4 MAG MBP MOG PLP1 TNF
21	charcot-marie-tooth disease	27.4	CNTF MAG MBP MPZ PLP1
22	multiple sclerosis	25.1	AQP4 CCR5 CNTF HLA-DRB1 LTA MAG
23	isolated optic neuritis	12.2
24	chronic relapsing inflammatory optic neuropathy	11.7
25	optic papillitis	11.3
26	microscopic polyangiitis	10.7	HLA-DRB1 TNF
27	beryllium disease	10.7	HLA-DRB1 TNF
28	autoimmune pancreatitis	10.7	HLA-DRB1 TNF
29	chronic beryllium disease	10.7	HLA-DRB1 TNF
30	anca-associated vasculitis	10.7	HLA-DRB1 TNF
31	lichen sclerosus	10.7	HLA-DRB1 TNF
32	acute hemorrhagic leukoencephalitis	10.6	AQP4 MBP
33	actinic prurigo	10.6	HLA-DRB1 TNF
34	nontuberculous mycobacterial lung disease	10.6	HLA-DRB1 TNF
35	microscopic colitis	10.6	HLA-DRB1 TNF
36	central nervous system vasculitis	10.6	HLA-DRB1 TNF
37	retinitis	10.6
38	rheumatoid vasculitis	10.6	HLA-DRB1 TNF
39	alveolar echinococcosis	10.5	HLA-DRB1 TNF
40	traumatic brain injury	10.5	AQP4 MBP
41	balo concentric sclerosis	10.5	AQP4 MBP MOG
42	internuclear ophthalmoplegia	10.5	AQP4 MBP MOG
43	mucocutaneous leishmaniasis	10.5	CCR5 TNF
44	hemorrhagic fever	10.5	HLA-DRB1 TNF
45	congenital hydrocephalus	10.4	MBP TNF
46	orofacial granulomatosis	10.4	CCR5 TNF
47	cranial nerve disease	10.3	AQP4 MOG MT-ND4
48	neuropathy	10.3
49	mannosidosis, beta a, lysosomal	10.3	MAG MBP
50	spondylarthropathy	10.3	LTA TNF

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):

Hypertension, Essential

Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:

Sources

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:

eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.07	MBP AQP4 MOG CCR5 MPZ CNTF
2	hematopoietic system	MP:0005397	10.02	MBP AQP4 MOG CCR5 MPZ CNTF
3	homeostasis/metabolism	MP:0005376	9.96	MBP AQP4 CCR5 MPZ CNTF PLP1
4	immune system	MP:0005387	9.9	MBP AQP4 MOG CCR5 MPZ CNTF
5	nervous system	MP:0003631	9.65	MBP AQP4 MOG CCR5 MPZ CNTF
6	vision/eye	MP:0005391	9.17	MBP AQP4 MOG CCR5 PLP1 LTA

Sources

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Methylprednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

83-43-2

6741

Prednisolone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

50-24-8

5755

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

53-03-2

5865

Glatiramer Acetate

Approved, Investigational

Phase 4,Phase 3,Phase 2

147245-92-9

3081884

Mycophenolate mofetil

Approved, Investigational

Phase 4

128794-94-5

5281078

Mycophenolic acid

Approved

Phase 4

24280-93-1

446541

Mitoxantrone

Approved, Investigational

Phase 4

65271-80-9

4212

Interferon beta-1a

Approved, Investigational

Phase 4,Phase 3

145258-61-3

6438354

Interferon beta-1b

Approved

Phase 4,Phase 2,Phase 3

145155-23-3

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

126941

Azithromycin

Approved

Phase 4

83905-01-5

55185 447043

Ciprofloxacin

Approved, Investigational

Phase 4

85721-33-1

2764

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Linezolid

Approved, Investigational

Phase 4

165800-03-3

441401

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 1

59-30-3

6037

leucovorin

Approved, Nutraceutical

Phase 4

58-05-9

143 6006

Adrenocorticotropic Hormone

Phase 4,Early Phase 1

Antiemetics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Inflammatory Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Autonomic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

beta-endorphin

Phase 4,Early Phase 1

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

glucocorticoids

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Melanocyte-Stimulating Hormones

Phase 4,Early Phase 1

Methylprednisolone acetate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Methylprednisolone Hemisuccinate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Neuroprotective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Prednisolone acetate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Prednisolone hemisuccinate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Prednisolone phosphate

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Protective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Adjuvants, Immunologic

Phase 4,Phase 3,Phase 2,Not Applicable

Antirheumatic Agents

Phase 4,Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 4,Phase 2

Antibiotics, Antitubercular

Phase 4

Anti-Infective Agents

Phase 4,Phase 2,Phase 3

Antitubercular Agents

Phase 4

Analgesics

Phase 4,Phase 2

Topoisomerase Inhibitors

Phase 4

Antimetabolites

Phase 4,Phase 3,Phase 2,Not Applicable

Vitamin B Complex

Phase 4,Phase 1

Antiviral Agents

Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 108)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis	Unknown status	NCT01838174	Phase 4	ACTHAR Gel (ACTH);IV steroids with oral taper
2	Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)	Unknown status	NCT00910598	Phase 4	glatiramer acetate
3	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Unknown status	NCT02809079	Phase 4	Mycophenolate mofetil;Prednisone
4	Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders	Unknown status	NCT02021825	Phase 4	Mitoxantrone
5	Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans	Completed	NCT00312325	Phase 4	Prednisolone
6	Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis	Completed	NCT00179478	Phase 4	interferon beta 1a 30 ug IM once weekly
7	Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse	Completed	NCT00753792	Phase 4	methylprednisolone;methylprednisolone;Placebo
8	A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults	Completed	NCT01427309	Phase 4
9	A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)	Completed	NCT00304291	Phase 4	Mitoxantrone
10	Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis	Completed	NCT01795872	Phase 4
11	Linezolid for Treatment of Nontuberculous Mycobacterial Diseases	Not yet recruiting	NCT03220074	Phase 4	Oral Tablet
12	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Terminated	NCT00854750	Phase 4	ACTHAR;ACTHAR;ACTHAR;ACTHAR
13	A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a	Withdrawn	NCT00771043	Phase 4	TYSABRI and AVONEX
14	Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.	Withdrawn	NCT00037115	Phase 4	interferon beta 1a;methotrexate;methylprednisolone
15	Simvastatin Treatment of Patients With Acute Optic Neuritis	Unknown status	NCT00261326	Phase 3	simvastatin;placebo
16	Optic Neuritis Treatment Trial (ONTT)	Unknown status	NCT00000146	Phase 3	Methylprednisolone;Prednisone
17	Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone	Unknown status	NCT00004645	Phase 3
18	Ampyra for Optic Neuritis in MS	Completed	NCT01337986	Phase 2, Phase 3	Dalfampridine/Placebo;Placebo/Dalfampridine
19	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)	Completed	NCT00856635	Phase 3	Glatiramer Acetate;placebo
20	Optic Neuritis Recovery After Oral or IV Corticosteroids	Completed	NCT01524250	Phase 2, Phase 3	corticosteroids;corticosteroids
21	Intravenous Immunoglobulin Therapy in Optic Neuritis	Completed	NCT00000117	Phase 3	Immunoglobulin
22	Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)	Completed	NCT01345240	Phase 3
23	Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients	Completed	NCT03002038	Phase 2, Phase 3	Azathioprine;Rituximab
24	Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)	Recruiting	NCT02376881	Phase 3	Erythropoietin
25	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders	Recruiting	NCT03350633	Phase 2, Phase 3	Tocilizumab Injection;Azathioprine
26	A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders	Recruiting	NCT03330418	Phase 3
27	Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD	Recruiting	NCT02028884	Phase 3	satralizumab (SA237);Placebo
28	A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	Recruiting	NCT02200770	Phase 2, Phase 3
29	Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial	Active, not recruiting	NCT01962571	Phase 3	Erythropoietin alfa;Placebo
30	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis	Active, not recruiting	NCT02220244	Phase 3	MD1003 100mg capsule
31	A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)	Active, not recruiting	NCT01892345	Phase 3	Eculizumab
32	Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD	Active, not recruiting	NCT02073279	Phase 3	satralizumab (SA237);Placebo
33	An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients	Enrolling by invitation	NCT02003144	Phase 3
34	MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)	Terminated	NCT01647880	Phase 2, Phase 3	Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
35	Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older	Terminated	NCT00976027	Phase 3
36	A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis	Terminated	NCT02398994	Phase 3	Intravenous Methylprednisolone;Intravenous Immunoglobulin
37	Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis	Withdrawn	NCT01337427	Phase 3	BIIB017
38	Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography	Unknown status	NCT01465893	Phase 2	Vitamin D;Vitamin D withheld
39	Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve	Unknown status	NCT01879527	Phase 2	Amiloride hydrochlorothiazide;Sugar pill
40	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Unknown status	NCT01364246	Phase 1, Phase 2
41	AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis	Unknown status	NCT01228396	Phase 2	Hyperimmune caprine serum against HIV lysate
42	Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders	Unknown status	NCT02249676	Phase 2
43	BIIB033 In Acute Optic Neuritis (AON)	Completed	NCT01721161	Phase 2	Placebo
44	Amiloride Clinical Trial In Optic Neuritis	Completed	NCT01802489	Phase 2	Amiloride;Placebo
45	Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis	Completed	NCT00355095	Phase 2	Erythropoietin
46	Neuroprotection With Phenytoin in Optic Neuritis	Completed	NCT01451593	Phase 2	Phenytoin;Placebo
47	Visual Reconstitution Therapy After Optic Neuritis	Completed	NCT01274702	Phase 2
48	Long-Term Assessment of Remyelinating Therapy	Completed	NCT02657915	Phase 2	Placebo;BIIB033 100mg/Kg
49	Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)	Completed	NCT00395200	Phase 1, Phase 2
50	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Completed	NCT02166346	Phase 2	Dalfampridine;Placebo

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Sources

Genetic Tests for Optic Neuritis

Sources

Anatomical Context for Optic Neuritis

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

¹⁹

Optic Nerve Which May Cause A Complete Or Partial Loss Of Vision

MalaCards organs/tissues related to Optic Neuritis:

⁴¹

Eye, Brain, T Cells, Testes, Bone, Pituitary, Spinal Cord

Sources

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 825)

#	Title	Authors	Year
1	Valuable Insights Into Visual Neuroplasticity After Optic Neuritis. ( 29297048 )	Toosy A.T.	2018
2	Early Nodal and Paranodal Disruption in Autoimmune Optic Neuritis. ( 29444299 )	Stojic A....Fairless R.	2018
3	Why Therapeutic Compliance in Optic Neuritis Deserves to Be More Than Just a Footnote: Response. ( 29923869 )	Morrow M.	2018
4	Anatomical Wiring and Functional Networking Changes in the Visual System Following Optic Neuritis. ( 29297053 )	Backner Y....Levin N.	2018
5	Paediatric ADEM followed by optic neuritis: disease course, treatment response and outcome. ( 29443442 )	Wong Y.Y.M....Neuteboom R.F.	2018
6	Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29259999 )	You Y....Klistorner A.	2018
7	Association of Optic Neuritis with <i>CYP4F2</i> Gene Single Nucleotide Polymorphism and IL-17A Concentration. ( 29736281 )	Banevicius M....Liutkeviciene R.	2018
8	Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. ( 29913164 )	Zhang Y....Yang H.	2018
9	Guillain-BarrAc syndrome and optic neuritis after Mycoplasma pneumoniae infection. ( 29429558 )	Matsunaga M....Kawano Y.	2018
10	Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. ( 29363529 )	Zhao Y....Wei S.	2018
11	Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. ( 29802557 )	Mori S....Nakamura M.	2018
12	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. ( 29808469 )	Tourbah A....Arndt C.	2018
13	Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein. ( 29972029 )	Ducloyer J.B....Lebranchu P.	2018
14	High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. ( 29249380 )	Bertsch-Gout M....Bernard J.	2018
15	Early Diagnosis of Recurrent Optic Neuritis Using Contrast-Enhanced T2 Fluid-attenuated Inversion Recovery Imaging: a Case Report. ( 29976284 )	Li H....Chen Z.Y.	2018
16	Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. ( 29766684 )	Seay M....Rucker J.C.	2018
17	Why Therapeutic Compliance in Optic Neuritis Deserves to be More Than Just a Footnote. ( 29901490 )	Gruener A.M....Chang J.R.	2018
18	Recurrent idiopathic neuroretinitis as a spectrum of atypical optic neuritis: a case report and literature review. ( 29538599 )	Viturino M.G.M....Moura F.C.	2018
19	Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )	Tajima Y....Mito Y.	2018
20	Typical optic neuritis? ( 29941727 )	Matalia J....Anaspure H.	2018
21	Relapsing acute disseminated encephalomyelitis followed by optic neuritis in children; a clinical entity associated with anti-MOG antibody. ( 29790244 )	Brilot F.	2018
22	Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. ( 29787495 )	Lu P....Sha Y.	2018
23	Erratum: Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. ( 29417957 )		2018
24	MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )	Dos Passos G.R....Sato D.K.	2018
25	Retinal nerve fiber layer and ganglion cell layer changes on optical coherence tomography in early multiple sclerosis and optic neuritis cases. ( 29283135 )	Pillay G....Saxena R.	2018
26	Advanced diffusion-weighted imaging in patients with optic neuritis deficit - value of reduced field of view DWI and readout-segmented DWI. ( 29417865 )	Seeger A....Hauser T.K.	2018
27	Recurrent Optic Neuritis as the Initial Symptom in Demyelinating Diseases. ( 29856159 )	FalcALo-GonAsalves A.B....de Oliveira E.M.L.	2018
28	Rituximab was effective for acute disseminated encephalomyelitis followed by recurrent optic neuritis with anti-myelin oligodendrocyte glycoprotein antibodies. ( 29661590 )	Nagashima M....Yamagata T.	2018
29	Baseline Brain Activity Changes in Patients With Single and Relapsing Optic Neuritis. ( 29731712 )	Ren Z....Mao B.	2018
30	Time to steroid treatment in severe acute optic neuritis. ( 29931830 )	Dale G.H....Bek T.	2018
31	Macular choroidal thickness and peripapillary retinal nerve fiber layer thickness in normal adults and patients with optic atrophy due to acute idiopathic demyelinating optic neuritis. ( 29856811 )	Park K.A....Oh S.Y.	2018
32	Incidence and Causes of Overdiagnosis of Optic Neuritis. ( 29222573 )	Stunkel L....Van Stavern G.P.	2018
33	Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis. ( 29445944 )	Kezuka T....Ishikawa H.	2018
34	Clinical Characteristics of Pediatric Optic Neuritis With Myelin Oligodendrocyte Glycoprotein Seropositive: A Cohort Study. ( 29778487 )	Chen Q....Tian G.	2018
35	A Pediatric Case of Relapsing-Remitting Multiple Sclerosis Onset following Varicella Zoster Ophthalmicus with Optic Neuritis. ( 29785316 )	Shiba N....Nakazawa Y.	2018
36	Unusual case of cerebral demyelination and bilateral optic neuritis in an infant with suppurative BCG lymphadenitis. ( 29848532 )	Anandakrishnan P....Khoo T.B.	2018
37	Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. ( 29938337 )	Lotan I....Stiebel-Kalish H.	2018
38	Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. ( 28914353 )	Biotti D....Deschamps R.	2017
39	Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. ( 28903961 )	Averseng-Peaureaux D....Cheuret E.	2017
40	Postinfectious Anti-Myelin Oligodendrocyte Glycoprotein Antibody Positive Optic Neuritis and Myelitis. ( 28820014 )	Vieira J.P....Brito M.J.	2017
41	No evidence of association between optic neuritis and secondary LHON mtDNA mutations in patients with multiple sclerosis. ( 28802665 )	Andalib S....Gjedde A.	2017
42	A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection. ( 29055448 )	Nakamura M....Kusaka H.	2017
43	Long-term structural retinal changes in patients with optic neuritis related to multiple sclerosis. ( 28860702 )	Andersen M.R....Grauslund J.	2017
44	Bevacizumab for Radiation Induced Optic Neuritis Among Aggressive Residual/Recurrent Suprasellar Tumors: More Than a Mere Antineoplastic Effect. ( 28754639 )	Dutta P....Mukherjee K.K.	2017
45	Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis. ( 28850630 )	Puthenparampil M....Gallo P.	2017
46	Optic neuritis in a patient with celiac disease. ( 28803640 )	Baghbanian S.M....Naser Moghadasi A.	2017
47	Optical Coherence Tomography and Subclinical Optical Neuritis in Longitudinally Extensive Transverse Myelitis. ( 29184337 )	Sinha P.K....Gupta G.	2017
48	Optic neuritis in dogs: 96 cases (1983-2016). ( 29251394 )	Smith S.M....Davidson M.G.	2017
49	Time is vision in recurrent optic neuritis. ( 28823952 )	Osinga E....Petzold A.	2017
50	Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )	Lochner P....Brigo F.	2017

Sources

Genes for Optic Neuritis

Genes related to Optic Neuritis (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	AQP4	Aquaporin 4	Protein Coding	37.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19140826 18510734 18509235 (more) 20019228 19917985
2	MBP	Myelin Basic Protein	Protein Coding	34.1	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7510787 7515411 7513391 (more) 7524258 8526468 7510098 7507500 7532318 9345452 7680141
3	MOG	Myelin Oligodendrocyte Glycoprotein	Protein Coding	33.52	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12732654
4	MAG	Myelin Associated Glycoprotein	Protein Coding	26.07	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7515411
5	PLP1	Proteolipid Protein 1	Protein Coding	25.26	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7515411 1373123 7510787 (more) 7510098 7524258
6	MT-ND4	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 4	Protein Coding	23.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	LTA	Lymphotoxin Alpha	Protein Coding	23.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8624683
8	TNF	Tumor Necrosis Factor	Protein Coding	22.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MPZ	Myelin Protein Zero	Protein Coding	22.04	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7524258 10618693 11985632
10	CCR5	C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)	Protein Coding	21.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	21.34	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	CNTF	Ciliary Neurotrophic Factor	Protein Coding	21.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	SOD3	Superoxide Dismutase 3	Protein Coding	20.84	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Optic Neuritis

ClinVar genetic disease variations for Optic Neuritis:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	MT-ND4	NC_012920.1: m.11443A> C	single nucleotide variant	Uncertain significance		GRCh37	Chromosome MT, 11443: 11443
2	MT-ND4	NC_012920.1: m.11443A> C	single nucleotide variant	Uncertain significance		GRCh38	Chromosome MT, 11443: 11443

Sources

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Sources

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Th1 Differentiation Pathway ⁶⁵ Show member pathways IL27-mediated signaling events ¹ IL-6-type cytokine receptor ligand interactions ⁶⁶ Interleukin-6 family signaling ⁶⁶ Interleukin-6 signaling ⁶⁶ Th17 Differentiation Pathway ⁶⁵	11.85	CNTF LTA TNF
2	Toxoplasmosis ³⁷ Show member pathways Leishmaniasis ³⁷	11.82	CCR5 HLA-DRB1 TNF
3	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.65	AQP4 PLP1 TNF
4	Cell adhesion molecules (CAMs) ³⁷	11.49	HLA-DRB1 MAG MPZ
5	Spinal Cord Injury ¹	11.34	AQP4 MAG MBP TNF
6	Cytokines and Inflammatory Response ¹	10.8	HLA-DRB1 TNF
7	Glial Cell Differentiation ¹	9.7	MAG MBP PLP1

Sources

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.96	AQP4 CCR5 HLA-DRB1 LTA MAG MBP
2	myelin sheath	GO:0043209	9.26	MAG MBP MPZ PLP1
3	compact myelin	GO:0043218	9.16	MAG MBP
4	external side of plasma membrane	GO:0009897	9.02	AQP4 CCR5 HLA-DRB1 MOG TNF
5	membrane	GO:0016020	10.06	AQP4 CCR5 HLA-DRB1 LTA MAG MBP

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	immune response	GO:0006955	9.65	CCR5 HLA-DRB1 LTA MBP TNF
2	response to hypoxia	GO:0001666	9.63	LTA MT-ND4 SOD3
3	negative regulation of growth of symbiont in host	GO:0044130	9.43	LTA TNF
4	cell-cell adhesion via plasma-membrane adhesion molecules	GO:0098742	9.4	MAG MPZ
5	central nervous system myelination	GO:0022010	9.37	MAG PLP1
6	myelination	GO:0042552	9.33	MBP MPZ PLP1
7	axon ensheathment	GO:0008366	9.32	MBP PLP1
8	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	8.96	LTA TNF
9	positive regulation of chronic inflammatory response to antigenic stimulus	GO:0002876	8.62	LTA TNF

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	tumor necrosis factor receptor binding	GO:0005164	9.16	LTA TNF
2	structural constituent of myelin sheath	GO:0019911	8.96	MBP PLP1
3	virus receptor activity	GO:0001618	8.8	CCR5 HLA-DRB1 MOG

Sources

Sources for Optic Neuritis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia